HLA-B54 is a candidate of response to Fluoropyrimidine plus PSK therapy in gastric cancer

It is not well known that the correlation between HLA antigens and response to cancer therapy. To evaluate the correlation among patients' outcome, HLA antigens and therapies, we used the hierarchical clustering analysis (Ward method). We examined HLA antigens as biomarkers as well as models of...

Full description

Saved in:
Bibliographic Details
Published in:Annals of Cancer Research and Therapy 2009/08/25, Vol.17(2), pp.40-44
Main Authors: Ogoshi, Kyoji, Isono, Kaichi
Format: Article
Language:English
Subjects:
FPSK
gastric cancer
HLA-B54
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is not well known that the correlation between HLA antigens and response to cancer therapy. To evaluate the correlation among patients' outcome, HLA antigens and therapies, we used the hierarchical clustering analysis (Ward method). We examined HLA antigens as biomarkers as well as models of gene polymorphism in 1753 gastric cancer patients followed over 25 years after treatment. Among these patients, we identified that HLA haplotypes; HLA-B54-Cw1-DQ4-DR4, might be restricting to Fluoropyrimidine drugs plus PSK therapy in gastric cancer. HLA haplotypes including HLA-B54 were candidate predictors for response to FPSK therapy in gastric cancer. HLAs will be useful biomarkers for response to therapy in Japanese patients.
ISSN:1344-6835
1880-5469
DOI:10.4993/acrt.17.40